Pomegranate Extract and Inflammageing
NCT05588479, Not applicable, Completed, Manchester Metropolitan University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Pomegranate Extract and Inflammageing | ClinicalTrials.gov |
| NCT number | NCT05588479 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 86 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Manchester Metropolitan University | ClinicalTrials.gov |
| Conditions | Aging | ClinicalTrials.gov |
| Interventions | Pomegranate extract, Control | ClinicalTrials.gov |
| First posted | 2022-10-20 | ClinicalTrials.gov |
| Last updated | 2025-01-20 | ClinicalTrials.gov |
Registered outcomes 21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Interleukin-6 (IL-6) levels | Baseline, week 6 & week 12 | Changes in IL-6 levels will be measured in a fasted blood sample using a commercially available assay kit. | ClinicalTrials.gov |
| Secondary | CRP (C-reactive protein) levels | Baseline, week 6 & week 12 | Changes in CRP levels will be measured in a fasted blood sample using a commercially available assay kit. | ClinicalTrials.gov |
| Secondary | Interleukin 1 (IL-1) levels | Baseline, week 6 & week 12 | Changes in IL-1 levels will be measured in a fasted blood sample using a commercially available assay kit. | ClinicalTrials.gov |
| Secondary | Interleukin 2 (IL-2) levels | Baseline, week 6 & week 12 | Changes in IL-2 levels will be measured in a fasted blood sample using a commercially available assay kit. | ClinicalTrials.gov |
| Secondary | Insulin growth factor-1 (IGF-1) levels | Baseline, week 6 & week 12 | Changes in IGF-1 levels will be measured in a fasted blood sample using a commercially available assay kit. | ClinicalTrials.gov |
| Secondary | Tumour necrosis factor (TNF-α) levels | Baseline, week 6 & week 12 | Changes in TNF-α levels will be measured in a fasted blood sample using a commercially available assay kit. | ClinicalTrials.gov |
| Secondary | Plasminogen Activator Inhibitor-1 (PAI-1) levels | Baseline, week 6 & week 12 | Changes in PAI-1 levels will be measured in a fasted blood sample using a commercially available assay kit. | ClinicalTrials.gov |
| Secondary | Telomerase activity | Baseline, week 6 & week 12 | Changes in telomerase activity will be measured in a fasted blood sample using a commercially available assay kit. | ClinicalTrials.gov |
| Secondary | Corsi block-tapping test | Baseline, week 6 & week 12 | Changes in working memory will be assessed using Corsi block-tapping computerised cognitive test. | ClinicalTrials.gov |
| Secondary | Rey Verbal Learning test | Baseline, week 6 & week 12 | Changes in working memory will be assessed using Rey Verbal Learning computerised cognitive test. | ClinicalTrials.gov |
| Secondary | Tower of Hanoi test | Baseline, week 6 & week 12 | Changes in executive function will be assessed using Tower of Hanoi computerised cognitive test. | ClinicalTrials.gov |
| Secondary | Wisconsin test | Baseline, week 6 & week 12 | Changes in executive function will be assessed using Wisconsin computerised cognitive test. | ClinicalTrials.gov |
| Secondary | Stroop test | Baseline, week 6 & week 12 | Changes in executive function will be assessed using Stroop computerised cognitive test. | ClinicalTrials.gov |
| Secondary | Digits span test | Baseline, week 6 & week 12 | Changes in working memory will be assessed using Digits span computerised cognitive test. | ClinicalTrials.gov |
| Secondary | Hand grip strength | Baseline, week 6 & week 12 | Changes in muscle strength will be assessed using hand grip strength physical test. | ClinicalTrials.gov |
| Secondary | Standing balance | Baseline, week 6 & week 12 | Changes in muscle function will be assessed using standing balance physical test. | ClinicalTrials.gov |
| Secondary | Gait speed | Baseline, week 6 & week 12 | Changes in muscle function will be assessed using gait speed physical test. | ClinicalTrials.gov |
| Secondary | Chair sit to stand | Baseline, week 6 & week 12 | Changes in muscle function will be assessed using chair sit to stand physical test. | ClinicalTrials.gov |
| Secondary | Fasting serum glucose levels | Baseline, week 6 & week 12 | Changes in glucose levels will be measured in a fasted blood sample using a commercially available assay kit. | ClinicalTrials.gov |
| Secondary | Fasting lipid levels | Baseline, week 6 & week 12 | Changes in lipid levels (TC, HDL, LDL \& TG) will be measured in a fasted blood sample using a commercially available assay kit. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Corsi Block-Tapping Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Tower of Hanoi | Secondary outcome | ConductCognition |
| Verbal Learning | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)